ArticleFrontiers in pharmacology2024
Trajectories of adherence to intravenous biological treatment in patients with inflammatory bowel disease: a longitudinal analysis.
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trajectories of Adherence to Biologics in Patients With Inflammatory Bowel Diseases: A Large-Scale Multi-Regional Italian Study Through the VALORE Distributed Database.Pharmacoepidemiology and drug safety · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long-term biological therapies for inflammatory bowel disease (IBD) include infliximab and vedolizumab, which are administered intravenously. Although highly effective, non-adherence to these biologics is common and is associated with adverse sequelae and loss of response. Objective: In this study, we aim to characterize long-term intravenous biologic adherence trajectories among IBD patients and identify the factors linked with these trajectories. Methods: We conducted a retrospective multicenter study of IBD patients over 2 years to assess their adherence to infliximab and vedolizumab. The date of infusion was determined based on medical and pharmacy records. Using group-based trajectory modeling (GBTM), adherence trajectories were identified based on patients' 90-day coverage of days over time. The effect of relevant variables on adherence behavior was assessed using multinomial regression analysis. Results: 374 patients with IBD were included in the study, 68.2% males with a median age of 34.3 (IQR 28.0-44.4) years old. Three distinct adherence trajectories were identified for intravenous biologics: "consistent adherence" (n = 136, 36.4%), "slow decline" (n = 137, 36.6%) and "rapid decline" (n = 101, 27.0%). Compared with consistent adherence, concomitant use of aminosalicylates (OR 3.49, 95% CI 1.34-9.05) was associated with a significantly greater risk of rapid decline. Conversely, being married at the initiation of biologics (OR 0.43, 95% CI 0.19-0.95) and having been hospitalized within preceding years (OR 0.44, 95% CI 0.23-0.88) appeared to have a protective effect against rapid decline. Additionally, being male (OR 0.57, 95% CI 0.32-1.01) was found to be protective against slow decline. Conclusion: Distinct adherence patterns for infusion biologics among IBD patients have been identified, offering valuable insights to refine the design and timing of adherence interventions. However, only limited factors were found to be associated with specific adherence trajectories, revealing the complex nature of adherence behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.